Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa Bay news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Charlotte news in your inbox

Catch up on the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Manuel Balce Ceneta / AP

Bloomberg reports that drug companies aren't so keen on Vice President Mike Pence's idea for a federal "right-to-try" law, which would allow dying patients to receive experimental drugs that have not yet been fully approved by the Food and Drug Administration.

Their reasoning: Right-to-try bypasses the FDA, which is a big worry for the pharmaceutical companies. Unapproved drugs may harm or even kill patients when their side effects haven't been widely tested. And if the treatment is still being researched, this might lead to the shutdown of more tightly-controlled clinical trials that could have allowed for wider adoption.

Why it matters: It's shaping up as another conflict between the Trump administration and the drug industry — and if the drug companies fight hard enough, getting it through Congress will be difficult.

Go deeper

Axios-Ipsos poll: Trust in federal coronavirus response surges

Data: Axios/Ipsos survey; Chart: Danielle Alberti/Axios

Trust surged in the federal government since President Biden's inauguration when it comes to COVID-19 — but that's almost entirely because of Democrats gaining confidence, according to the latest installment of the Axios/Ipsos Coronavirus Index.

The big picture: Americans reported the biggest improvement in their mental and emotional health since our survey began last March, and the highest trust levels since April about the federal government providing them accurate virus information and looking out for their best interests.

7 hours ago - Politics & Policy

McConnell drops filibuster demand, paving way for power-sharing deal

Senate Majority Leader Chuck Schumer (R) and Minority Leader Mitch McConnell attend a joint session of Congress. Photo: Olivier Douliery/AFP via Getty Images

Senate Minority Leader Mitch McConnell has abandoned his demand that Democrats state, in writing, that they would not abandon the legislative filibuster.

Between the lines: McConnell was never going to agree to a 50-50 power sharing deal without putting up a fight over keeping the 60-vote threshold. But the minority leader ultimately caved after it became clear that delaying the organizing resolution was no longer feasible.

8 hours ago - Technology

Scoop: Google won't donate to members of Congress who voted against election results

Sen. Ted Cruz led the group of Republicans who opposed certifying the results. Photo: Stefani Reynolds/Pool/AFP via Getty Images

Google will not make contributions from its political action committee this cycle to any member of Congress who voted against certifying the results of the presidential election, following the deadly Capitol riot.

Why it matters: Several major businesses paused or pulled political donations following the events of Jan. 6, when pro-Trump rioters, riled up by former President Trump, stormed the Capitol on the day it was to certify the election results.